Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Nicola Tarantino, Francesco Santoro, Luisa De Gennaro, Michele Correale, Francesca Guastafierro, Antonio Gaglione, Matteo Di Biase & Natale Daniele Brunetti. (2017) Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vascular Health and Risk Management 13, pages 29-41.
Read now
Read now
Theodosios Filippatos, Eleftheria Tzavella, Christos Rizos, Moses Elisaf & George Liamis. (2017) Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. Expert Opinion on Drug Safety 16:10, pages 1121-1132.
Read now
Read now
Nicola Ferri, Alberto Corsini, Cesare Sirtori & Massimiliano Ruscica. (2017) PPAR-α agonists are still on the rise: an update on clinical and experimental findings. Expert Opinion on Investigational Drugs 26:5, pages 593-602.
Read now
Read now
T. D. Filippatos, M. Florentin, M. Georgoula & M. S. Elisaf. (2017) Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 10:2, pages 187-200.
Read now
Read now
T. D. Filippatos, E. Klouras, F. Barkas & M. Elisaf. (2016) Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Review of Cardiovascular Therapy 14:8, pages 953-962.
Read now
Read now
T. D. Filippatos & M. S. Elisaf. (2016) Pitavastatin and carbohydrate metabolism: what is the evidence?. Expert Review of Clinical Pharmacology 9:7, pages 955-960.
Read now
Read now
Anastazia A. Kei, Theodosios D. Filippatos & Moses S. Elisaf. (2016) The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opinion on Drug Safety 15:4, pages 559-569.
Read now
Read now
Articles from other publishers (10)
Alan Chait. (2023) Multifactorial chylomicronemia syndrome. Current Opinion in Endocrinology, Diabetes & Obesity.
Crossref
Crossref
Agata Górniak, Hanna Czapor-Irzabek, Adrianna Złocińska, Agnieszka Gawin-Mikołajewicz & Bożena Karolewicz. (2023) Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders. Pharmaceutics 15:2, pages 603.
Crossref
Crossref
Myung Soo Park, Jong-Chan Youn, Eung Ju Kim, Ki Hoon Han, Sang Hak Lee, Sung Hea Kim, Byung Jin Kim, Sung Uk Kwon & Kyu-Hyung Ryu. (2021) Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study. Clinical Therapeutics 43:10, pages 1735-1747.
Crossref
Crossref
Alan ChaitRobert H. Eckel. (2019) The Chylomicronemia Syndrome Is Most Often Multifactorial. Annals of Internal Medicine 170:9, pages 626.
Crossref
Crossref
Guido Filler & Ravneet NagraGuido Filler & Ravneet Nagra. 2019. Becoming a Successful Scholar. Becoming a Successful Scholar
13
22
.
Guido Filler, Sepideh Taheri, Christopher McIntyre, Connor Smith, Lakshmimathy Subramanian, Gerhard Fusch & Christoph Fusch. (2018) Chronic kidney disease stage affects small, dense low-density lipoprotein but not glycated low-density lipoprotein in younger chronic kidney disease patients: a cross-sectional study. Clinical Kidney Journal 11:3, pages 383-388.
Crossref
Crossref
Jonathan N. Johnson & Guido Filler. (2018) The importance of cardiovascular disease in pediatric transplantation and its link to the kidneys. Pediatric Transplantation 22:3, pages e13146.
Crossref
Crossref
Hongliang Li, Sung Eun Shin, Mi Seon Seo, Jin Ryeol An, Won-Kyo Jung, Kwon-Soo Ha, Eun-Taek Han, Seok-Ho Hong, Hyoweon Bang, Young Min Bae, Amy L. Firth, Il-Whan Choi & Won Sun Park. (2017) The PPARα activator fenofibrate inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells. European Journal of Pharmacology 812, pages 155-162.
Crossref
Crossref
Lu Han, Wen-Jun Shen, Stefanie Bittner, Fredric B Kraemer & Salman Azhar. (2017) PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α. Future Cardiology 13:3, pages 259-278.
Crossref
Crossref
Xin Sun, Yan Zhang & Meilin Xie. (2017) The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease. Acta Pharmaceutica 67:1, pages 1-13.
Crossref
Crossref